Title: 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer
Authors: SATHEKGE MIKEBRUCHERTSEIFER FRANKKNOESEN OTTOREYNEKE FLENGANA TLAWAL IBOSHOMANE TMOKOALA KVORSTER MARIZAMORGENSTERN ALFRED
Citation: JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES vol. 50 no. 1 p. S30
Publisher: ELSEVIER BV
Publication Year: 2019
JRC N°: JRC116489
ISSN: 1939-8654 (online)
URI: http://publications.jrc.ec.europa.eu/repository/handle/JRC116489
DOI: 10.1016/j.jmir.2019.03.091
Type: Articles in periodicals and books
Abstract: 225Ac- Prostate-specific membrane antigen (PSMA)-617 is a highly promising novel compound for therapy of prostate cancer. A remarkable therapeutic efficacy has been demonstrated in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients, with xerostomia as the main side effect. A promising strategy for minimization of side effects is based on optimization of the dosing regime while maintaining sufficient therapeutic efficacy for several cohorts of patients, including chemotherapy-naïve patients.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.